StockData
Nkarta, Inc. logo

Nkarta, Inc. (NKTX) stock

NKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$1.15−0.10 (-8.00%)

Close on Nov 18, 2026Market cap $82.37MP/E –Yield 0.00%

Nkarta operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Nkarta's operating income for the twelve months ending Jun 30, 2026 was -$132.25M. For fiscal 2025 it was -$122.00M. The highest annual figure on record is -$22.35M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$122.00M–
FY2024Dec 31, 2024-$128.19M–
FY2023Dec 31, 2023-$131.65M–
FY2022Dec 31, 2022-$118.96M–
FY2021Dec 31, 2021-$86.43M–
FY2020Dec 31, 2020-$51.51M–
FY2019Dec 31, 2019-$22.35M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$43.13M–
Q1 FY2026Mar 31, 2026-$30.88M–
Q4 FY2025Dec 31, 2025-$30.96M–
Q3 FY2025Sep 30, 2025-$27.29M–
Q2 FY2025Jun 30, 2025-$27.19M–
Q1 FY2025Mar 31, 2025-$36.56M–
Q4 FY2024Dec 31, 2024-$30.92M–
Q3 FY2024Sep 30, 2024-$33.79M–
Q2 FY2024Jun 30, 2024-$30.72M–
Q1 FY2024Mar 31, 2024-$32.76M–
Q4 FY2023Dec 31, 2023-$31.19M–
Q3 FY2023Sep 30, 2023-$29.29M–
Q2 FY2023Jun 30, 2023-$36.86M–
Q1 FY2023Mar 31, 2023-$34.31M–
Q4 FY2022Dec 31, 2022-$34.98M–
Q3 FY2022Sep 30, 2022-$30.26M–
Q2 FY2022Jun 30, 2022-$27.61M–
Q1 FY2022Mar 31, 2022-$26.10M–
Q4 FY2021Dec 31, 2021-$22.89M–
Q3 FY2021Sep 30, 2021-$22.43M–
Q2 FY2021Jun 30, 2021-$21.63M–
Q1 FY2021Mar 31, 2021-$19.48M–
Q4 FY2020Dec 31, 2020-$18.00M–
Q3 FY2020Sep 30, 2020-$13.75M–
Q2 FY2020Jun 30, 2020-$10.36M–
Q1 FY2020Mar 31, 2020-$9.41M–
Q4 FY2019Dec 31, 2019-$8.65M–
Q3 FY2019Sep 30, 2019-$5.91M–
Q2 FY2019Jun 30, 2019-$4.67M–

More Nkarta figures

See a number that looks wrong?